High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma
By C. Linnemann, M. V. Buuren, L. Bies, E. Verdegaal, R. Schotte, J. Calis, Sam Behjati, A. Velds, H. Hilkmann, Dris el Atmioui and 6 more. Nature Medicine, 2014
654 citations recorded by the source corpus.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/0d943c6fed2e4effa6e79db902fc0b87f3ff5a52
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
- Padmanee Sharma
- P. Greenberg
- James P. Allison
- A. Schietinger
- M. Philip
- John Sidney
- Catherine J. Wu
- Nir Hacohen
In Oncology
Citations in the corpus
- Immune Checkpoint Targeting in Cancer Therapy: Towards Combination Strategies with Curative Potential (2015, background): “In contrast, immune checkpoint therapy is inherently multivalent because targeting a single checkpoint can potentially release T cells with specificity for peptides derived from many different antigens present in a tumor, including differentiation, cancer testis, and even neoantigens generated by mu”
- A comprehensive review and performance evaluation of bioinformatics tools for HLA class I peptide-binding prediction (2020, background): “the final step of experimentally verifying neo-epitopes [13, 14].”